{"brief_title": "Pediatric Epilepsy Trial in Subjects 1-24 Months", "brief_summary": "This study is being conducted to evaluate the effectiveness and safety of LAMICTAL added to the current therapy of pediatric patients age 1-24 months old with partial seizures. The medication used in this study has been approved by FDA for the adjunctive treatment of partial seizures in patients 2 years and older.", "condition": ["Epilepsy"], "intervention_type": ["Drug"], "intervention_name": ["lamotrigine"], "criteria": "INCLUSION CRITERIA: - Have a confident diagnosis of epilepsy - Must be experiencing 4 or more reliably detectable partial seizures per month while receiving at least 1 anti-epileptic drug (AED) - Must weigh at least 7 lbs if currently receiving enzyme inducing antiepileptic drugs (EIADs) OR weigh at least 15 lbs if currently receiving non-enzyme inducing antiepileptic drugs (non-EIADs) - Have no underlying chronic metabolism problems - Have normal lab results - Have a normal electrocardiogram (ECG) EXCLUSION CRITERIA: - Have a diagnosis of severe, progressive myoclonus. - Have seizures not related to epilepsy. - Have previously demonstrated sensitivity or allergic reaction to the study drug or its related compounds. - Have progressive or unstable condition of the nervous system. - Used experimental medication within 30 of enrollment into the study. - Have any significant, chronic heart, kidney, liver or stomach/intestinal (GI) condition. - Current use of the medication felbamate. - Current use of adrenocorticotrophic hormone (ACTH). - Following a ketogenic diet. - Receiving vagal nerve stimulation (VNS).", "gender": "All", "minimum_age": "1 Month", "maximum_age": "24 Months", "healthy_volunteers": "No", "keyword": "epilepsy", "mesh_term": ["Epilepsy", "Lamotrigine"], "id": "NCT00043875"}